Seeking Alpha Liptruzet has atorvastatin (generic Lipitor) in it instead of simavastatin (generic Zocor), and what that is supposed to accomplish is a mystery to me. It's a mystery to Josh Bloom over at the American Council for Science and Health, too, and he's out ... and more »
Western News Titled Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients, the paper covers a study that looked at a large group of patients who took both Lipitor and generic atorvastatin over a prolonged period of time, ultimately ...
Family Practice News Digital Network Since the results of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) study were released in 2008, the value of adding ezetimibe has been questioned. In that controversial study, the combination of ...
pharmabiz.com The sales in North America declined to Rs.689 crore from Rs.2,093 crore in the same quarter of last year as it included sales of two exclusivity viz., ato...
Monthly Prescribing Reference Merck announced that the FDA has approved Liptruzet (ezetimibe and atorvastatin ) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patient with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet ...
PharmaTimes The agency has approved Liptruzet (ezetimibe and atorvastatin ) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidaemia as adjunctive therapy to diet. Taken once-daily, Merck says ...
Medscape Dallas, Texas— The US Food and Drug Administration (FDA) has approved a new lipid-lowering combination tablet that includes atorvastatin , which went off patent in 2011, and ezetimibe (Zetia, Merck/Schering-Plough. The combination, known as Liptruzet, ...
DailyFinance LIPTRUZET (pronounced LIP-true-zett) contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin , currently one of the most wide...
Wall Street Journal Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET(TM) (ezetimibe and atorvastatin ) tablets for the treatment of elevated low-density ...
